SynthesisFluids and barriers of the CNS2026
Convergent blood-brain barrier breakdown in schizophrenia and autism spectrum disorders: a systematic review of preclinical animal models.
Synthesis in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia (SCZ) and autism spectrum disorder (ASD) are neurodevelopmental disorders with multifactorial origins involving genetic and environmental risk factors. Both conditions share overlapping pathophysiological mechanisms, including neuroinflammation, synaptic dysfunction, and circuit-level disturbances. Emerging evidence implicates blood-brain barrier (BBB) dysfunction as a potential common element in their pathogenesis. Specifically, BBB disruption is a recurring feature in preclinical models of SCZ and ASD, suggesting its role as a transdiagnostic mechanism in neurodevelopmental disorders. This systematic review aims to evaluate BBB alterations-including permeability, integrity, developmental changes, and tight junction (TJ) protein expression-in rodent models of SCZ- and ASD-like phenotypes.
methodsFollowing PRISMA guidelines, we screened experimental studies assessing BBB status in murine models of SCZ and ASD compared to wild type rodents. Inclusion criteria focused on models based on genetic manipulation and environmental insults. Included studies consistently reported BBB alterations across diverse models.
resultsFindings showed disrupted TJ protein expression (claudin-5, occludin, ZO-1), increased permeability, and endothelial dysfunction. Both genetic (e.g., Shank3, 22q11.2 deletion, etc.) and environmental (e.g., maternal immune activation, valproate exposure, etc.) models exhibited BBB abnormalities. Pharmacological and experimental interventions targeting the BBB-such as claudin-5 modulation or β-catenin signaling-ameliorated BBB damage and behavioral phenotypes.
conclusionsThat BBB disruption is a recurring feature in preclinical models of SCZ and ASD suggests its pursuit as a transdiagnostic mechanism in neurodevelopmental disorders. However, as many findings rely on single studies, further replication is essential. Future studies should explore sex differences, critical developmental windows, and therapeutic strategies aimed at restoring BBB function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.